Recombinant Mouse EDA2R/TNFRSF27/XEDAR Fc Chimera, CF

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse EDA2R/TNFRSF27/XEDAR Fc Chimera, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse EDA2R/TNFRSF27/XEDAR Fc Chimera is coated at 0.1 μg/mL (100 μL/well), the concentration of Recombinant Human EDA‑A2/Ectodysplasin A2 (Catalog # 922-ED) that produces 50% of the optimal binding response is 3‑15 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse EDA2R/TNFRSF27/XEDAR protein
  

  Mouse XEDAR/EDA2R (Met1-Thr138) Accession # Q8BX35	IEGRMDP	Mouse IgG2A (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q8BX35
• N-terminal Sequence: Met1
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: Eda2r
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 42.6 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 57-60 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse EDA2R/TNFRSF27/XEDAR Fc Chimera, CF

• ectodysplasin A2 receptor
• EDA2R
• EDA-A2 receptor
• EDAA2R
• EDA-A2R
• EDAA2Rtumor necrosis factor receptor superfamily member XEDAR
• EDAR2
• TNFRSF27
• XEDAR
• XEDARTNFRSF27tumor necrosis factor receptor superfamily member 27
• X-linked ectodysplasin-A2 receptor

Background

X‑linked Ectodysplasin Receptor (XEDAR), also known as EDA2R and TNFRSF27, is an approximately 45 kDa transmembrane protein in the TNF receptor superfamily (1). Mature mouse XEDAR consists of a 138 amino acid (aa) extracellular domain (ECD) with three tandem TNFR cysteine‑rich domains, a 21 aa transmembrane segment, and a 138 aa cytoplasmic domain. Within the ECD, mouse XEDAR shares 87% and 96% aa sequence identity with human and rat XEDAR, respectively. A 20 kDa fragment of the ECD can be shed by metalloprotease mediated cleavage (2). XEDAR binds selectively to the EDA‑A2 variant of Ectodysplasin (EDA), while the closely related receptor EDAR binds selectively to the EDA‑A1 variant (3). Other than a 2 aa deletion in its TNF‑like domain, EDA‑A2 is identical to EDA‑A1 (3). Mutations in both EDAR and EDA are associated with hypohidrotic ectodermal dysplasia (HED), a disorder of hair, tooth, and eccrine sweat gland morphogenesis (4). XEDAR itself is strongly associated with androgenetic alopecia (male hair loss) (5). XEDAR is widely expressed, notably in embryonic basal epidermal cells and maturing hair follicles (3, 6, 7). Even though it does not contain a cytoplasmic death domain, XEDAR can associate with Fas and induce EDA‑A2 dependent apoptosis (6, 8). Its transcription is directly induced by p53, and XEDAR mediated cell death is p53 dependent (6, 9). XEDAR is down‑regulated in breast, colon, and lung cancers, particularly in cases with p53 mutations (6, 10). XEDAR also plays a role in EDA‑A2 induced skeletal muscle degeneration and osteoblast differentiation (7, 11).

1. Pfeffer, K. (2003) Cytokine Growth Factor Rev. 14:185.
2. Tanikawa, C. et al. (2010) Mol. Cancer Res. 8:855.
3. Yan, M. et al. (2000) Science 290:523.
4. Mikkola, M.L. (2009) Am. J. Med. Genet. 149A:2031.
5. Prodi, D.A. et al. (2008) J. Invest. Dermatol. 128:2268.
6. Tanikawa, C. et al. (2009) Oncogene 28:3081.
7. Newton, K. et al. (2004) Mol. Cell. Biol. 24:1608.
8. Sinha, S.K. and P.M. Chaudhary (2004) J. Biol. Chem. 279:41873.
9. Brosh, R. et al. (2010) FEBS Lett. 584:2473.
10. Punj, V. et al. (2010) Clin. Cancer Res. 16:1140.
11. Chang, B. et al. (2007) Cancer Gene Ther. 14:927.

Bioinformatics

• Gene Symbol: Eda2r
• Uniprot:
  • Q8BX35()